Evidence map›Paper›PMID 42100776›Full record

ArticleFrontiers in psychiatry2026

Acupuncture for irritable bowel syndrome comorbid with anxiety and depression: study protocol for a placebo run-in, randomized clinical trial.

Xuezhou Wang, Weijuan Gang, Xiaoyan Wang, Hang Zhou, Jin Huo, Yingying Wang, Rongjun Li, Lingyu Qi

Abstract read
In one paragraph

Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuezhou WangThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
Weijuan GangThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
Xiaoyan WangThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
Hang ZhouInternational Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.
Jin HuoThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
Yingying WangThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
Rongjun LiThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.
Lingyu QiThe Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastrointestinal and psychological symptoms jointly motivate patients with irritable bowel syndrome (IBS) to seek medical care, with the latter often exacerbating the difficulty of achieving overall improvement. Although acupuncture has been shown to improve gastrointestinal symptoms in the general IBS population, the evidence in individuals with psychological disturbances remains insufficient. Methods: This will be a placebo run-in, randomized controlled trial. After the 1-week sham acupuncture intervention run-in period, the 80 eligible IBS patients without strong placebo responses will be randomly assigned to the true acupuncture (TA) group and sham acupuncture (SA) group. During the 4-week intervention period, all patients will receive the assigned intervention three times per week, followed by an 8-week follow-up. The primary endpoint is the response rate, defined as the proportion of patients with a decrease of greater than or equal to 50 points in the IBS Symptom Severity Scale (IBS-SSS) score from baseline at week 4. Secondary outcomes include the response rates at other time points, original IBS-SSS scores, Hospital Anxiety and Depression Scale (HADS), Visual Analog Scale (VAS) for abdominal pain, satisfaction with bowel habits, blinding assessment, and Credibility/Expectancy Questionnaire. Safety will be monitored and recorded during the trial. Discussion: This trial will provide individualized evidence for addressing IBS with key comorbidities while excluding placebo response. The results of this trial will be published in a peer-reviewed journal. Clinical Trial Registration: https://itmctr.ccebtcm.org.cn/mgt/project/view/1985616257155727360, identifier ITMCTR2025002100.

Indexed as

acupunctureirritable bowel syndromemental healthprotocolrandomized controlled trial

Identifiers

PMID42100776
PMCPMC13143963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.